Divarasib vs Fulzerasib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline

Divarasib

Developed by Roche

Phase 3 in Non-Small Cell Lung Cancersmall molecule
Partial signal

NCT06497556 · Phase 3 · active, not recruiting

The trial is randomized with a real active comparator (sotorasib or adagrasib) and a hard clinical endpoint (progression-free survival), and it reportedly met that endpoint with a statistically significant benefit. However, the study is open-label with no blinding of participants or investigators, which limits confidence in outcome assessment despite blinded independent central review of scans, so it falls short of the strongest tier of evidence.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT04302025 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) (Up to approximately 4 years): Krascendo 1 (NCT06497556): divarasib met its primary endpoint (PFS) and key secondary endpoint (OS) vs sotorasib/adagrasib, described as clinically meaningful and statistically significant improvements. (met)

Result source: NCT06497556

Fulzerasib · Dupert

Marketed by Innovent Biologics under a licence from GenFleet Therapeutics

Phase 2 in Non-Small Cell Lung Cancersmall molecule
Weak signal

NCT05756153 · Phase 1/2 · completed

KROCUS was a single-arm, open-label Phase 1b/2 trial of fulzerasib plus cetuximab in previously untreated KRAS G12C-mutated non-small-cell lung cancer, with 47 patients treated at 30 centres. The Phase 2 primary endpoint was the investigator-assessed objective response rate, and the confirmed rate was 69% (90% CI 56 to 80). With no comparator arm and no formal success threshold reported, no result can be called met or missed. Treatment-related adverse events occurred in 87% of patients, grade 3 in 15%, with no grade 4 or 5 events. The figures come from the final peer-reviewed report (Gregorc et al., Lancet Oncol 2026).

Single-arm response rate with no comparator and no formal statistical threshold.

Next expected readout: March 2027 · NCT07492342 (registry estimate)

Reported efficacy

Phase Ib: adverse events (28 days); Phase II: objective response rate (up to 1 year after last patient in): Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. (not_applicable)

Result source: NCT05756153

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDivarasibFulzerasib
PFS, median—Trial running · NCT03178552—Trial running · NCT07601048
OS, median—Trial running · NCT03178552—Trial running · NCT07601048
ORR—Trial running · NCT03178552—Trial running · NCT07601048
Duration of response, median—Trial running · NCT03178552—Trial running · NCT07601048

PFS, median

Divarasib
—Trial running · NCT03178552
Fulzerasib
—Trial running · NCT07601048

OS, median

Divarasib
—Trial running · NCT03178552
Fulzerasib
—Trial running · NCT07601048

ORR

Divarasib
—Trial running · NCT03178552
Fulzerasib
—Trial running · NCT07601048

Duration of response, median

Divarasib
—Trial running · NCT03178552
Fulzerasib
—Trial running · NCT07601048
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Divarasib
Krascendo 1 (NCT06497556): divarasib met its primary endpoint (PFS) and key secondary endpoint (OS) vs sotorasib/adagrasib, described as clinically meaningful and statistically significant improvements. NCT06497556 · Phase 3 · design grade: moderate · publication or press release
Fulzerasib
Confirmed investigator-assessed objective response rate per RECIST 1.1 (Phase 2 primary), fulzerasib 600 mg twice daily plus cetuximab, single arm, first-line KRAS G12C NSCLC: 69% (90% CI 56 to 80); 47 patients treated; data cutoff 14 January 2025. NCT05756153 · Phase 1/2 · design grade: weak · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Divarasib's landscape · Fulzerasib's landscape